{"Title": "Extending the scope of PARP inhibitors in ovarian cancer", "Year": 2019, "Source": "Lancet Oncol.", "Volume": "20", "Issue": 4, "Art.No": null, "PageStart": 470, "PageEnd": 472, "CitedBy": 2, "DOI": "10.1016/S1470-2045(19)30019-1", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063569823&origin=inward", "Abstract": null, "AuthorKeywords": null, "IndexKeywords": ["Carcinoma, Ovarian Epithelial", "Female", "Humans", "Ovarian Neoplasms", "Phosphatidylinositol 3-Kinases", "Phthalazines", "Piperazines", "Poly(ADP-ribose) Polymerase Inhibitors", "Thiazoles"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 2, "EID": "2-s2.0-85063569823", "SubjectAreas": [["Oncology", "MEDI", "2730"]], "AuthorData": {"7007134127": {"Name": "Ledermann J.A.", "AuthorID": "7007134127", "AffiliationID": "60109234, 60012754, 60022148", "AffiliationName": "Cancer Research UK & UCL Cancer Trials Centre, UCL Cancer Institute, University College London"}}}